Q3 2025 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Nov 4, 2025 / 01:30 PM GMT

Release Date Price: €12.03 (+5.90%)

Transcript 8-K10-Q

Key Points

Positve

Aurinia Pharmaceuticals Inc (AUPH) reported a 27% year-over-year growth in Lupkynis sales for Q3 2025.
The company raised its 2025 sales guidance for Lupkynis to $265 million to $270 million, marking the second increase this year.
Net income for Q3 2025 was $31.6 million, up 119% from the same period in 2024.
Cash flows from operating activities increased by 162% to $44.5 million compared to Q3 2024.
Aurinia Pharmaceuticals Inc (AUPH) is advancing its novel biologic, ARI Intercept, into clinical studies for autoimmune diseases by the end of 2025.

Negative

Aurinia Pharmaceuticals Inc (AUPH) is involved in a legal complaint against Dr. George Titmarsh, which is pending in court.
The company received an information request from the FDA, indicating potential regulatory scrutiny.
Anti-drug antibodies were detected in the majority of subjects at certain dose levels in the ARI Intercept study.
The presence of multiple competitors in the autoimmune disease space could impact market share.
Uncertainty remains regarding the specific indications and trial designs for ARI Intercept, with details expected only in early 2026.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AUPH.OQ - Aurinia Pharmaceuticals Inc
Q3 2025 Aurinia Pharmaceuticals Inc Earnings Call
Nov 04, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. Welcome to the Iranian Pharmaceuticals 3rd quarter 2025 conference call.

Please be advised that a Q&A session will follow Orinia's prepared remarks.

I now turn the call over to Peter Greenly, President and Chief Executive Officer of Orania.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you all for joining us to discuss Orinia's 3rd quarter 2025 update.

Joining me on the call today are Joe Miller, our Chief Financial Officer, and Doctor Greg Keenan, our Chief Medical Officer.

Before we begin our

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.